Protein aggregation

Clinical Chemistry and Laboratory Medicine

Volumn 39, Issue 11, 2001, Pages 1065-1075

  Merlini, G ^a   Bellotti, V ^a   Andreola, A ^a   Palladini, G ^a   Obici, L ^a   Casarini, S ^a   Perfetti, V ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Amyloidosis; Light chain deposition disease; Neurodegenerative disorders; Protein conformational diseases

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; GLUTAMINE; HEMOGLOBIN; PRION PROTEIN; SERINE PROTEINASE INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALZHEIMER DISEASE; ARTICLE; BRAIN DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; LABORATORY DIAGNOSIS; MUTATION; PARKINSON DISEASE; PH; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FOLDING; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN TERTIARY STRUCTURE; SICKLE CELL ANEMIA; TEMPERATURE;

AMYLOIDOSIS; CLINICAL CHEMISTRY TESTS; HUMANS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEINS;

EID: 0035213152     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2001.172     Document Type: Article

References (89)

1. Protein misfolding, evolution and disease
2. Protein folding: Progress made and promises ahead
3. From Levinthal to pathways to funnels
4. Illuminating folding intermediates
5. Posttranslational quality control: Folding, refolding, and degrading proteins
6. Conformational disease
7. Conformational changes and disease - Serpins, prions and Alzheimer's
8. Shattuck lecture - Neurodegenerative diseases and prions
9. Prions
10. Prions: Disease propagation and disease therapy by conformational transmission
11. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
12. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
13. Kinetic theory of fibrillogenesis of amyloid beta-protein
14. The biophysics of sickle cell hydroxyurea therapy
15. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein
16. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: Implications for wild-type, V30M, and L55P amyloid fibril formation
17. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease
18. Watching amyloid fibrils grow by time-lapse atomic force microscopy
19. X-ray diffraction studies on amyloid filaments
20. A molecular model of the amyloid fibril
21. The protofilament substructure of amyloid fibrils
22. Amyloid fibrils from muscle myoglobin
23. Common core structure of amyloid fibrils by synchrotron X-ray diffraction
24. Nomenclature of amyloid fibril proteins. Report from the meeting of the International Nomenclature Committee on Amyloidosis, Aug 8-9, 1998
25. Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs
26. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing
27. Structural diversity of ex vivo amyloid fibrils studied by cryo-electron microscopy
28. 2-microglobulin
29. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda)
30. Nephrotoxic potential of Bence Jones proteins
31. Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence
32. A role for destabilizing amino acid replacements in light-chain amyloidosis
33. Structural characterization of kappa II Inc, a new amyloid immunoglobulin
34. Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains
35. Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications
36. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
37. FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation
38. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants
39. 2-microglobulin facilitates protein aggregation and fibril formation
40. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro
41. Pathogenic light chains and the B-cell repertoire
42. Amino acid sequence of a kappa I primary (AL) amyloid protein (AND)
43. Comparison of the amino acid sequences of ten kappa 1 amyloid proteins for amyloidogenic sequences
44. Structural bases of light chain-related pathology
45. Thermodynamic instability of human lambda 6 light chains: Correlation with fibrillogenicity
46. Four structural risk factors identify most fibril-forming kappa light chains
47. The amino acid sequence of the glycosylated amyloid immunoglobulin light chain protein AL MS
48. Glycosylation of immunoglobulin light chains associated with amyloidosis
49. A glycosylated Bence Jones protein and its autologous amyloid light chain containing potentially amyloidogenic residues
50. Local water bridges and protein conformational stability
51. Glycoproteins: Their structure, biosynthesis and possible clinical implications
52. 2-microglobulin facilitates protein aggregation and fibril formation
53. Review: Immunoglobulin light chain amyloidosis - The archetype of structural and pathogenic variability
54. Amyloid P component. A critical review
55. A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis
56. Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis
57. Apolipoprotein E and amyloidogenesis
58. Laminin interactions with the apoproteins of acute-phase HDL: Preliminary mapping of the laminin binding site on serum amyloid A
59. Proteoglycans in amyloidogenesis
60. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation
61. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation
62. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis
63. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease
64. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: Association with dominant amyloid-related organ involvement and survival after stem cell transplantation
65. The tropism of organ involvement in primary systemic amyloidosis: Contributions of Ig V(L) germ line gene use and clonal plasma cell burden
66. Protein misfolding and disease; protein refolding and therapy
67. Genetic neurodegenerative diseases: The human illness and transgenic models
68. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
69. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
70. The use of transgenic mice in the investigation of transmissible spongiform encephalopathies
71. Spontaneous neurodegeneration in transgenic mice with mutant prion protein
72. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide
73. Single and multiple transgenic mice as models for Alzheimer's disease
74. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
75. Amyloid diseases: Abnormal protein aggregation in neurodegeneration
76. Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease
77. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis
78. Amyloids: Tombstones or triggers?
79. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains
80. Monoclonal gammapathies
81. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine
82. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis
83. Mechanisms of disease: Monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease
84. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases
85. Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease
86. Amino acid sequence of κ Sci, the Bence Jones protein isolated from a patient with light chain deposition disease
87. Structural and functional characterization of three human immunoglobulin kappa light chains with different pathological implications
88. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates
89. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding